CN109922810A - 心肌梗塞的重构的高密度脂蛋白治疗 - Google Patents

心肌梗塞的重构的高密度脂蛋白治疗 Download PDF

Info

Publication number
CN109922810A
CN109922810A CN201780069271.4A CN201780069271A CN109922810A CN 109922810 A CN109922810 A CN 109922810A CN 201780069271 A CN201780069271 A CN 201780069271A CN 109922810 A CN109922810 A CN 109922810A
Authority
CN
China
Prior art keywords
rhdl
event
patient
mol
apolipoprotein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780069271.4A
Other languages
English (en)
Chinese (zh)
Inventor
S·赖特
C·施尔勒
D·丹德瑞
A·吉尔
D·杜非
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSL Ltd
Original Assignee
CSL Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CSL Ltd filed Critical CSL Ltd
Priority to CN202310189946.6A priority Critical patent/CN116196395A/zh
Publication of CN109922810A publication Critical patent/CN109922810A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
CN201780069271.4A 2016-11-10 2017-11-10 心肌梗塞的重构的高密度脂蛋白治疗 Pending CN109922810A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310189946.6A CN116196395A (zh) 2016-11-10 2017-11-10 心肌梗塞的重构的高密度脂蛋白治疗

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662420050P 2016-11-10 2016-11-10
US62/420,050 2016-11-10
US201762472240P 2017-03-16 2017-03-16
US62/472,240 2017-03-16
PCT/AU2017/051232 WO2018085890A1 (en) 2016-11-10 2017-11-10 Reconstituted high density lipoprotein treatment of myocardial infarction

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202310189946.6A Division CN116196395A (zh) 2016-11-10 2017-11-10 心肌梗塞的重构的高密度脂蛋白治疗

Publications (1)

Publication Number Publication Date
CN109922810A true CN109922810A (zh) 2019-06-21

Family

ID=62109053

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780069271.4A Pending CN109922810A (zh) 2016-11-10 2017-11-10 心肌梗塞的重构的高密度脂蛋白治疗
CN202310189946.6A Pending CN116196395A (zh) 2016-11-10 2017-11-10 心肌梗塞的重构的高密度脂蛋白治疗

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202310189946.6A Pending CN116196395A (zh) 2016-11-10 2017-11-10 心肌梗塞的重构的高密度脂蛋白治疗

Country Status (12)

Country Link
US (2) US20200038481A1 (enExample)
EP (1) EP3538105A4 (enExample)
JP (2) JP2019533705A (enExample)
KR (2) KR20240044543A (enExample)
CN (2) CN109922810A (enExample)
AU (2) AU2017358402B2 (enExample)
BR (1) BR112019007709A2 (enExample)
CA (1) CA3043110A1 (enExample)
IL (1) IL266428B2 (enExample)
MX (1) MX2019005459A (enExample)
SG (2) SG11201903945XA (enExample)
WO (1) WO2018085890A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017081561A1 (en) 2015-11-09 2017-05-18 Revamp Medical Ltd. Blood flow reducer for cardiovascular treatment
CN113195038B (zh) * 2018-12-11 2025-12-30 瑞普医药有限公司 用于调节体腔中的血流量的系统、装置以及方法
EA202191890A1 (ru) 2019-01-18 2022-02-03 Астразенека Аб Ингибиторы pcsk9 и способы их применения
US11248001B2 (en) 2019-01-18 2022-02-15 Astrazeneca Ab PCSK9 inhibitors and methods of use thereof
WO2025210584A1 (en) * 2024-04-04 2025-10-09 CSL Innovation Pty Ltd Reconstituted high density lipoprotein treatment of myocardial infarction

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103118683A (zh) * 2010-06-30 2013-05-22 Csl有限公司 重建高密度脂蛋白制剂及其生产方法
WO2015044459A1 (en) * 2013-09-30 2015-04-02 Université Pierre Et Marie Curie - Paris 6 (Upmc) Reconstituted high density lipoproteins composition and uses thereof
CN104755096A (zh) * 2012-11-02 2015-07-01 Csl有限公司 重构的hdl配制剂

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040067873A1 (en) * 2002-05-17 2004-04-08 Dasseux Jean-Louis H. Method of treating dyslipidemic disorders
KR20190084334A (ko) 2011-12-21 2019-07-16 시에스엘 리미티드 아포지질단백질 제형을 위한 용량 용법
US20160074473A1 (en) * 2014-07-31 2016-03-17 Kinemed, Inc. Effect of phospholipid composition of reconstituted hdl on its cholesterol efflux and anti-inflammatory properties

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103118683A (zh) * 2010-06-30 2013-05-22 Csl有限公司 重建高密度脂蛋白制剂及其生产方法
CN105396122A (zh) * 2010-06-30 2016-03-16 杰特有限公司 重建高密度脂蛋白制剂及其生产方法
CN104755096A (zh) * 2012-11-02 2015-07-01 Csl有限公司 重构的hdl配制剂
WO2015044459A1 (en) * 2013-09-30 2015-04-02 Université Pierre Et Marie Curie - Paris 6 (Upmc) Reconstituted high density lipoproteins composition and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CSLBEHRING: "A Study of CSL112 in Adults With Moderate Renal Impairment and Acute Myocardial Infarction", 《CLINICALTRIALS.GOV》 *
HAMID MORADI等: "Reverse Cholesterol Transport Pathway in Experimental Chronic Renal Failure", 《AMERICAN JOURNAL OF NEPHROLOGY》 *

Also Published As

Publication number Publication date
RU2019117552A (ru) 2020-12-10
MX2019005459A (es) 2019-08-12
EP3538105A4 (en) 2020-05-20
SG10201911714YA (en) 2020-02-27
BR112019007709A2 (pt) 2019-07-09
KR20240044543A (ko) 2024-04-04
US20240207357A1 (en) 2024-06-27
CN116196395A (zh) 2023-06-02
SG11201903945XA (en) 2019-05-30
AU2017358402A1 (en) 2019-04-18
JP2019533705A (ja) 2019-11-21
EP3538105A1 (en) 2019-09-18
CA3043110A1 (en) 2018-05-17
AU2017358402B2 (en) 2023-10-05
US20200038481A1 (en) 2020-02-06
IL266428B2 (en) 2024-12-01
IL266428A (en) 2019-06-30
KR20190084095A (ko) 2019-07-15
IL266428B1 (en) 2024-08-01
AU2023282314A1 (en) 2024-01-18
JP7464654B2 (ja) 2024-04-09
RU2019117552A3 (enExample) 2021-06-25
JP2022116254A (ja) 2022-08-09
WO2018085890A1 (en) 2018-05-17

Similar Documents

Publication Publication Date Title
US20240207357A1 (en) Reconstituted high density lipoprotein treatment of myocardial infarction
von Eckardstein et al. High-density lipoprotein revisited: biological functions and clinical relevance
JP7167281B2 (ja) 酸性スフィンゴミエリナーゼ欠乏症に対する用量漸増酵素補充療法
Feingold Triglyceride lowering drugs
Groeneveld et al. Intrahepatic fibrin (ogen) deposition drives liver regeneration after partial hepatectomy in mice and humans
Papakonstantinou et al. Metabolic syndrome and cardiometabolic risk factors
Orekhov et al. Anti-atherosclerotic therapy based on botanicals
Kondreddy et al. Factor VIIa induces anti-inflammatory signaling via EPCR and PAR1
Paty et al. Reversibility of the anti‐FXa activity of idrabiotaparinux (biotinylated idraparinux) by intravenous avidin infusion
Baeyens et al. Limitations of IL-2 and rapamycin in immunotherapy of type 1 diabetes
Wei et al. Spermine inhibits endoplasmic reticulum stress-induced apoptosis: a new strategy to prevent cardiomyocyte apoptosis
CN109789217A (zh) 用于降低脂蛋白颗粒对动脉壁酶引起的致动脉粥样硬化性聚集的敏感度的方法和试剂盒
Kovarik et al. Effects of angiotensin-converting-enzyme inhibitor therapy on the regulation of the plasma and cardiac tissue renin-angiotensin system in heart transplant patients
Magisetty et al. Selective inhibition of activated protein C anticoagulant activity protects against hemophilic arthropathy in mice
TW202128184A (zh) 酒精性肝炎之治療
JP2015504088A (ja) 肝疾患の治療
Kim et al. Conversion of twice-daily to once-daily tacrolimus is safe in stable adult living donor liver transplant recipients
Venkatakrishnan et al. A pharmacokinetic, pharmacodynamic, and electrocardiographic study of liposomal mifamurtide (L-MTP-PE) in healthy adult volunteers
Malmström et al. No effect of lipid lowering on platelet activity in patients with coronary artery disease and type 2 diabetes or impaired glucose tolerance
Fukunaga et al. Lipoprotein (a) as a risk factor for silent cerebral infarction in hemodialysis patients
RU2798830C2 (ru) Лечение восстановленным липопротеином высокой плотности инфаркта миокарда
Ingle et al. Secret in the eyes-fish eye disease
Miller et al. Idarucizumab for reversal of dabigatran-associated bleeding: misnomer or miracle?
WO2025210584A1 (en) Reconstituted high density lipoprotein treatment of myocardial infarction
Holmqvist et al. FRI0117 Diabetes in rheumatoid arthritis: Incidence and association with RA treatment

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20190621

RJ01 Rejection of invention patent application after publication